Idea Transcript
STATE OF CALIFORNIA
Budget Change Proposal - Cover Sheet DF-46 (REV 08/16)
Fiscal Year
Business Unit
2017-18
1111
Department Consumer Affairs
Priority No. 1
Program
Budget Request Name 1111-049-BCP-2017-GB
Subprogram
1210 - C A L I F O R N I A S T A T E BOARD OF PHARMACY
Budget Request Description Staff for Outsourcing Facilities and Automated Delivery Systems (Senate Bill 1193) Budget Request Summary The California State Board of Pharmacy (Board) is requesting special fund expenditure authorization in the amount of $481,000 in fiscal year 2017-18 and $449,000 in 2018-19 ongoing to fund a 1.0 Supervising Pharmacy Inspector, 2.0 Pharmacy Inspectors and a 0.5 Office Technician to regulate the provisions set forth in Chapter 484, Statutes of 2016 (Senate Bill (SB) 1193). Chapter 484 requires the Board to license both resident and non-resident outsourcing facilities and requires that the outsourcing facility location be inspected prior to issuance or renewal of a license. Additionally, Chapter 484 requires a pharmacy to register an automated drug delivery system with the Board within 30 days of installation and on an annual basis as part of the license renewal.
Requires Legislation •
Yes
^
Code Section(s) to be Added/Amended/Repealed No
•
Does this BCP contain information technology (IT) components? • Yes [E] No If yes, departmental
Chief Information
Officer must
Department CIO
Date
sign.
For IT requests, specify the project number, the most recent project approval document (FSR, SPR, S1BA, S2AA, S3SD, S4PRA), and the approval date. Project No.
Project Approval Document:
Approval Date:
If proposal affects another department, does other department concur with proposal? Attach comments
of affected
department,
signed and dated by the department
•
director or
Yes
Prepared By
Date
Reviewed By
Date
Department Director
Date
Agency Secretary
Date
Additional Review: •
BCP Type: PPBA
Capital Outlay
•
Policy
-ByTiffany Garcia
•
ITCU
•
•
FSCU
•
OSAE
•
CALSTARS
•
No
Dept. of Technology
Workload Budget per Government Code 13308.05 Date submitted to the Legislature
ilMn
•
designee.
BCP Fiscal Detail Sheet B C P Title: Pharmacy - Outsourcing Facility Audits and Auto Delivery S y s t e m s ( S B 1193)
B R Name: 1111-049-BCP-2017-GB
Budget Request Summary
FY17 CY
BY
BY+1
BY+2
BY+3
BY+4
Personal Services Positions - Permanent
0.0
3.5
3.5
3.5
3.5
3.5
Total Positions
0.0
3.5
3.5
3.5
3.5
3.5
Salaries and Wages Earnings - Permanent Total Salaries and Wages
0
281
281
281
281
281
$0
$281
$281
$281
$281
$281
0
149
149
149
149
149
$0
$430
$430
$430
$430
$430
0 0 0 0 0 0 0 0
6 2 4 2 1 2 2 32
6 2 4 2 1 2 2 0
6 2 4 2 1 2
6 2
6 2
4 2 1 2
4 2
2 0
2 0
2 0
Total Operating E x p e n s e s and Equipment
$0
$51
$19
$19
$19
$19
Total Budget Request
$0
$481
$449
$449
$449
$449
Total Staff Benefits Total Personal S e r v i c e s Operating Expenses and Equipment 5301 5302 5304 5306 5320 5322 5344 5368
- General Expense - Printing - Communications - Postage - Travel: In-State - Training - Consolidated Data Centers - Non-Capital Asset Purchases - Equipment
1 2
und Summary Fund Source - State Operations 0767 - Pharmacy Board Contingent Fund,
0
481
449
449
449
449
Total State Operations Expenditures
$0
$481
$449
$449
$449
$449
Total All Funds
$0
$481
$449
$449
$449
$449
481
449
449
449
449
$0
$481
$449
$449
$449
$449
Program Summary Program Funding 1210 - California State Board of Pharmacy Total All Programs
BR Name: 1111-049-BCP-2017-GB
B C P Title: Pharmacy - Outsourcing Facility Audits and Auto Delivery S y s t e m s ( S B 1193)
Personal S e r v i c e s Details
Positions 11398874 8876 -
Salary Information Mid
Min
Max
Office Techn (Typing) Supvng Inspector Inspector
Total Positions Salaries and Wages 1139 8874 8876 Total Salaries
Office Techn (Typing) Supvng Inspector Inspector and Wages
Staff Benefits 5150350 5150500 5150600 5150800 -
Health Insurance OASDI Retirement - General Workers'Compensation
Total Staff Benefits Total Personal Services
CY 0 0 0
19 92 170
BY 0.5 1.0 2.0
BY+1 0.5 1.0 2.0
BY+2 0.5 1.0 2.0
BY+3 0.5 1.0 2.0
BY+4 0.5 1.0 2.0
0.0
3.5
3.5
3.5
3.5
3.5
BY+2
BY+1
BY
CY 0.0 0.0 0.0
19 92 170
BY+4
BY+3 19 92 170
19 92
19 92 170
170
$0
$281
$281
$281
$281
$281
0 0 0 0
44 21 75 9
44 21 75 9
44 21 75 9
44 21 75 9
44 21 75 9
$0
$149
$149
$149
$149
$149
$430
$430
$430
$430
$430
$0
A n a l y s i s of P r o b l e m
A.
Budget Request Summary T h e California State Board of P h a r m a c y (Board) is requesting special f u n d expenditure authorization in the a m o u n t of $ 4 8 1 , 0 0 0 in fiscal y e a r 2 0 1 7 - 1 8 a n d $ 4 4 9 , 0 0 0 in 2 0 1 8 - 1 9 ongoing to f u n d a 1.0 Supervising P h a r m a c y Inspector, 2.0 P h a r m a c y Inspectors and a 0.5 Office T e c h n i c i a n to regulate the provisions set forth in C h a p t e r 4 8 4 , Statutes of 2 0 1 6 (Senate Bill (SB) 1193). C h a p t e r 4 8 4 requires the Board to license both resident a n d non-resident outsourcing facilities a n d requires that the outsourcing facility location be i n s p e c t e d prior to issuance or renewal of a license. Additionally, Chapter 4 8 4 requires a p h a r m a c y to register a n a u t o m a t e d drug delivery s y s t e m w i t h the Board within 30 days of installation a n d o n a n annual basis as part of the license renewal.
B.
Background/History T h e N o v e m b e r 2 0 1 3 e n a c t m e n t of the federal D r u g Quality a n d Security A c t r e s p o n d e d to a 2 0 1 2 c o m p o u n d i n g t r a g e d y (where a p h a r m a c y c o m p o u n d e d a product that w a s c o n t a m i n a t e d by fungal material) in a n e w w a y : this legislation created a n e w type of entity authorized to c o m p o u n d m e d i c a t i o n s - the outsourcing facility. T h e s e generally large-scale production facilities are authorized to c o m p o u n d large quantities of m e d i c a t i o n s for use by other entities, w h e r e a s a p h a r m a c y generally c o m p o u n d s p u r s u a n t to a patient-specific prescription. Medications p r e p a r e d by outsourcing facilities must be d o n e under current g o o d m a n u f a c t u r i n g practices (or c G M P s ) , w h i c h are m o r e stringent than c o m p o u n d i n g r e q u i r e m e n t s for sterile c o m p o u n d i n g p h a r m a c i e s , since m a n y patients in multiple locations c a n receive these medications that are not usually linked to patient-specific prescriptions. C h a p t e r 4 8 4 expressly authorizes that a facility that is registered as an outsourcing facility with the F o o d a n d D r u g A d m i n i s t r a t i o n ( F D A ) shall be concurrently licensed with the Board as an outsourcing facility. C h a p t e r 4 8 4 e n s u r e s consistent oversight over outsourcing facilities doing business within or into California a n d i m p r o v e s c o n s u m e r protection. S u c h facilities play an important role in ensuring a c c e s s to medications that w o u l d otherwise not be available to patients as s u c h are d r u g s are in short supply. B e c a u s e of the inherent risks that c o m e with c o m p o u n d i n g , u n d e r the provisions of C h a p t e r 4 8 4 , a license for a n outsourcing facility shall not be issued or r e n e w e d until the location is inspected by the Board a n d f o u n d to be in c o m p l i a n c e . A license for a n outsourcing facility shall not be issued or r e n e w e d until: •
T h e Board reviews a current c o p y of the facilities policies a n d p r o c e d u r e s for sterile a n d n o n sterile c o m p o u n d i n g
•
T h e facility m u s t provide copies of all federal and state regulatory agency inspection reports, accreditation reports and certification reports of facilities or e q u i p m e n t p r e m i s e s c o n d u c t e d in t h e prior 12 m o n t h s
•
Prior to inspection, the B o a r d must receive a list of all sterile d r u g s a n d nonsterile drug products c o m p o u n d e d by the p h a r m a c y as reported to the F D A within the prior 12 m o n t h s
T h e o u t s o u r c i n g facility shall also provide the Board with the following: •
A c o p y of any disciplinary action or other action t a k e n by a n o t h e r state or the F D A within 10 d a y s of the action
•
Notice within 2 4 hours or any recall notice issued by the non-resident outsourcing facility
•
A c o p y of any complaint it received involving an outsourcing facility's c o m p o u n d e d products f r o m or involving any provider, p h a r m a c y or patient in California within 72 hours of receipt and
•
Notice within 2 4 hours after learning of a d v e r s e effects reported or potentially attributable to a nonresident outsourcing facility's product.
C o m p o u n d i n g p h a r m a c i e s are especially important t o d a y to p r o d u c e n e e d e d medications that are in short supply. However, it is equally important that c o m p o u n d i n g requirements are a d h e r e d to by these facilities a n d m o n i t o r e d for c o m p l i a n c e if being administered to California residents. C h a p t e r 4 8 4 adds l:\Unit\BCP\DF-46_Cover_Sheet_ August 2016.doc
A n a l y s i s of P r o b l e m
to the strength of the state's oversight of facilities that c o m p o u n d non-patient specific drug products. Oversight of o u t s o u r c i n g facilities is vital to the protection of California c o n s u m e r s . California law currently permits use of a u t o m a t e d drug delivery devices w h i c h are m e c h a n i c a l s y s t e m s controlled by a p h a r m a c i s t or other specified health c a r e providers to provide s t o r a g e , dispensing and distribution of d a n g e r o u s d r u g s a n d devices. Use of t h e s e delivery d e v i c e s p r o m o t e s control and the ability to maintain all transaction information, to accurately track the m o v e m e n t of drugs into and out of t h e device, for security, a c c u r a c y a n d accountability while providing f o r quality, potency a n d purity of the m e d i c a t i o n s . U n d e r s o m e provisions, the p h a r m a c i s t must authorize the release of medication. T h e d e m a n d for additional use of t h e s e delivery d e v i c e s is g r o w i n g . A pilot study is currently undenway that if proven v a l u a b l e , w o u l d allow patients to pick up medication f r o m a delivery d e v i c e that is not specifically located in a p h a r m a c y as long as patient consultation is first provided. P u r s u a n t to C h a p t e r 4 8 4 , a p h a r m a c y that o w n s or provides d a n g e r o u s drugs d i s p e n s e d t h r o u g h an a u t o m a t e d d r u g delivery s y s t e m shall register the s y s t e m by providing the Board in writing with the location of e a c h device within 30 d a y s of installation a n d on an a n n u a l basis as part of the license r e n e w a l . A p h a r m a c y m a y only use an a u t o m a t e d delivery s y s t e m if the following conditions are met:
•
Use of the a u t o m a t e d d r u g delivery s y s t e m is consistent with legal requirements
•
T h e p h a r m a c y ' s policies a n d p r o c e d u r e s related to the a u t o m a t e d drug delivery s y s t e m include appropriate security m e a s u r e s a n d monitoring of the inventory to prevent theft and diversion
•
T h e p h a r m a c y report d r u g losses f r o m the a u t o m a t e d drug delivery s y s t e m as required by law
•
T h e p h a r m a c y license is unexpired a n d not subject to disciplinary condition
T h e registration of t h e s e a u t o m a t e d drug delivery s y s t e m s is a beneficial step in Board oversight and enforcement. Resource History (Dollars in thousands) Program Budget
PY-4
PY-2
PY-3
PY-1
PY
Authorized Expenditures
$14,521
$15,057
$18,155
$20,850
$22,031
Actual Expenditures
$12,924
$13,851
$16,719
$19,350
$21,678
Revenues
$12,703
$13,933
$14,674
$18,227
$18,843
Authorized Positions
79.2
83.5
79.8
80.8
100.8
Filled Positions
59.0
71.5
74.8
80.8
93.8
Vacancies
20.2
12.0
5.0
0.0
7.0
0.
state Level Considerations T h i s proposal is consistent with the Board's m a n d a t e to m a k e public protection its first priority. m a n d a t e is articulated in B u s i n e s s a n d Professions C o d e section 4 0 0 1 . 1 w h i c h states:
This
"Protection of the public shall be the highest priority for the California State Board of P h a r m a c y in exercising its licensing, regulatory a n d disciplinary functions. W h e n e v e r protection of the public is inconsistent with other interests s o u g h t to be p r o m o t e d , the protection of the public shall be paramount."
l:\Unit\BCP\DF-46_Cover_Sheet_August2016.doc
A n a l y s i s of P r o b l e m
D.
Justification O n S e p t e m b e r 2 2 , 2 0 1 6 , the O o v e r n o r s i g n e d S B 1193 w h i c h c o n t a i n e d m a n y important c o n s u m e r protection provisions. Effective J a n u a r y 1, 2 0 1 7 , any facility registered as a n outsourcing facility with the F D A n e e d s to be concurrently licensed with the B o a r d as a n o u t s o u r c i n g facility if it c o m p o u n d s nonpatient specific medication for distribution within or into California. T h e Board is requesting a 1.0 Supervising P h a r m a c y Inspector, 2.0 P h a r m a c y Inspectors. O u t s o u r c i n g inspections are labor intense. A n o u t s o u r c i n g inspection will require at least t h r e e full w o r k i n g d a y s using t w o inspectors. T h e Supervising P h a r m a c y Inspector is n e c e s s a r y to m a n a g e a n d o v e r s e e the inspectors to provide direction, monitoring, leadership a n d continuous training. Supervising Inspectors are responsible to review the w o r k product of the P h a r m a c y Inspector, including but not limited to, inspection review, investigation review, report review, inspection/case a s s i g n m e n t s a n d m a n a g e r i a l duties. D e p e n d i n g on the level of complexity of the inspection, s o m e inspections will require m o r e t h a n t h r e e d a y s with two inspectors. G i v e n the r e s o u r c e s required to perform these inspections, the Supervising P h a r m a c y Inspector will assist with the m o s t c o m p l e x inspections w h e n necessary. T h e Board's P h a r m a c y Inspectors w o r k in the field c o n d u c t i n g pre-licensure, post licensure a n d routine inspections in addition to inspections as a result of c o m p l a i n t s received f r o m c o n s u m e r s . T h e s e positions are necessary to p r o c e s s the provisions of C h a p t e r 4 8 4 to license and regulate approximately 6 5 outsourcing facilities. T h e half-time Office T e c h n i c i a n position is being r e q u e s t e d to p r o c e s s registrations for a u t o m a t e d drug delivery s y s t e m s . It is e s t i m a t e d that data entry for approximately 3,000 a u t o m a t e d drug delivery s y s t e m s will be p r o c e s s e d . If the Board d o e s not receive the additional staffing to meet the n e w r e q u i r e m e n t s of C h a p t e r 4 8 4 , it will be f o r c e d to m a k e difficult decisions to redirect staff f r o m other a r e a s of critical n e e d . This will c a u s e investigations of c o m p l a i n t s to be p o s t p o n e d and c a u s e u n d u e risk to Californians w h o have a r e a s o n a b l e e x p e c t a t i o n that their drug supply is safe a n d properly m o n i t o r e d by the state. Failure to provide t h e s e inspections m e a n s a failure to uphold the Board's public protection m a n d a t e .
E.
O u t c o m e s and Accountability C h a p t e r 7 9 9 , Statutes of 2 0 1 6 ( S B 1039) w a s s i g n e d by the G o v e r n o r o n S e p t e m b e r 2 9 , 2016. This bill adjusts the B o a r d ' s f e e structure by increasing the statutory c a p s for a majority of the Board's fees. T h e a t t a c h e d f u n d condition s h o w s the projected revenue increase with the Board's n e w fee structure. T h e B o a r d will be able to sustain its existing operations with an appropriate reserve level with the i m p l e m e n t a t i o n of the Board's n e w f e e structure.
F.
A n a l y s i s of All F e a s i b l e A l t e r n a t i v e s 1.
Provide the B o a r d with 3.5 positions a n d $ 4 8 1 , 0 0 0 in 2 0 1 7 - 1 8 a n d $ 4 4 9 , 0 0 0 in 2 0 1 8 - 1 9 o n g o i n g to f u n d a 1.0 Supervising P h a r m a c y Inspector, 2.0 P h a r m a c y Inspectors a n d a 0.5 Office T e c h n i c i a n . Pro: This alternative w o u l d allow the Board to fully a d h e r e to t h e provisions set forth in Chapter 4 8 4 while maintaining its current level of c o n s u m e r protections C o n : Not approving this alternative will f o r c e the Board to redirect staff f r o m other mission critical a r e a s . T h i s w o u l d be inconsistent with the Board's m a n d a t e of protecting the public.
2.
Provide the B o a r d with 3.0 positions a n d $ 4 3 9 , 0 0 0 in 2 0 1 7 - 1 8 a n d $ 4 1 5 , 0 0 0 in 2 0 1 8 - 1 9 ongoing to f u n d 1.0 Supervising Inspector a n d 2.0 P h a r m a c y Inspectors. Pro: This alternative w o u l d allow the Board to partially a d h e r e to the provisions set forth in C h a p t e r 4 8 4 albeit not to a n appropriate level. C o n : This alternative w o u l d require the Board to redirect r e s o u r c e s f r o m other mission critical areas to provide support for the P h a r m a c y Inspectors a n d process the registrations of the a u t o m a t e d delivery s y s t e m s .
l:\Unit\BCP\DF-46_Cover_Sheet_August2016.doc
A n a l y s i s of P r o b l e m
3.
Provide t h e B o a r d with 2.0 positions a n d $ 2 8 5 , 0 0 0 in 2 0 1 7 - 1 8 a n d $ 2 6 9 , 0 0 0 in 2 0 1 8 - 1 9 ongoing to f u n d 2.0 P h a r m a c y inspectors. Pro: T h i s alternative w o u l d allow the Board to partially a d h e r e to t h e provisions set forth in Chapter 4 8 4 albeit not to a n a p p r o p r i a t e level. C o n : T h e B o a r d lacks sufficient resources to appropriately m a n a g e the outsourcing facility p r o g r a m . Further, with the reduction in r e s o u r c e s , t h e r e could be delays in t i m e inspecting facilities w h i c h could result in s h o r t a g e of non-patient specific c o m p o u n d e d d r u g s being available to California patients a n d c a u s e additional stress on a drug m a r k e t that is already experiencing a shortage. Further, the Board will lack t h e resources n e c e s s a r y to process the registrations of the a u t o m a t e d delivery s y s t e m s m a k i n g m a n a g i n g of s u c h information extremely challenging. This w o u l d require the Board to redirect r e s o u r c e s f r o m other mission critical a r e a s , w h i c h is inconsistent with the Board's m a n d a t e of protecting the public.
4.
Status Q u o - T h i s should not be a n option as it will result in the Board's inability to implement the c o n s u m e r protection provisions c o n t a i n e d in C h a p t e r 4 8 4 . T h e Board will lack the resources n e e d e d to regulate o u t s o u r c i n g facilities w h i c h will have a significant and detrimental effect on California c o n s u m e r s . Further, t h e Board will be unable to readily identify the use of a u t o m a t e d delivery s y s t e m s a n d therefore unable to e n s u r e they are being u s e d consistent with the provisions of the law. Pro: This alternative w o u l d not require additional f u n d i n g . C o n : If the B o a r d d o e s not receive the additional staffing to m e e t the n e w r e q u i r e m e n t s of Chapter 4 8 4 , it will be f o r c e d to m a k e difficult decisions to redirect staff f r o m other areas of critical n e e d . This will c a u s e investigations of complaints to be p o s t p o n e d a n d c a u s e undue risk to Californians w h o h a v e a r e a s o n a b l e e x p e c t a t i o n that their drug supply is safe a n d properly monitored by the state. Failure to provide t h e s e inspections m e a n s a failure to u p h o l d the Board's public protection mandate.
G.
Implementation P l a n T h e B o a r d will initiate the hiring process using the position authority a n d funding received to recruit for the a p p r o v e d position.
H.
S u p p l e m e n t a l Information Please see the attached w o r k l o a d , f u n d condition a n d organization chart.
I.
Recommendation T h e B o a r d r e c o m m e n d s alternative o n e as it is t h e only option that will allow the Board to meet the r e q u i r e m e n t s of C h a p t e r 4 8 4 w h i l e e n s u r i n g the safety of Californians and preventing any additional s h o r t a g e of an already strained d r u g supply.
l:\Unit\BCP\DF-46_Cover_Sheet_August 2016.doc
SB 1193 Outsourcing Facilities and Automated Drug Delivery Systems Workload Chart
O f f i c e T e c h n i c i a n (0.5) W o r k l o a d FY 2017-18
Data e n t r y o n locations o f a u t o m a t e d d r u g delivery
# TIMES
HOURS T O
TOTAL
TASK
REFORM
TIME/HOURS
PERFORMED
TASK
ANNUALLY
3,000
0.25
750
500
0.09
45
52
2
104
systems Process M a i l A d m i n Functions ( e - m a i l , m e e t i n g s , etc.) Total Time
899 h o u r s Positions N e e d e d
S u p e r v i s i n g I n s p e c t o r (1.0) W o r k l o a d FY 2017-18
O.S
# TIMES TASK
HOURSTO
TOTAL
PERFORMED
REFORM TASK
TIME/HOURS ANNUALLY*
Review Policies a n d P r o c e d u r e s / P r o d u c t Lists
5
8
40
Outsourcing Inspections**
9
40
360
Assign Inspections
63
1
63
Review Recalls/ADRs f o r Possible Investigation
50
2
100
FDA 4 8 3 - Reconciliation (including FDA Liaison)
12
4
48
Assign Investigations (Plan a n d Assessments, etc.)
15
1
15
Review Investigation Reports
15
4
60
1
80
80
52
8
416
W e e k l y Supervisor C o n f e r e n c e Calls
48
1.5
72
M o n t h l y C o n f e r e n c e M e e t i n g s w i t h Staff
12
3
36
6
8
48
12
32
384
6
16
96
CGMP T r a i n i n g Supervisor Duties (guidance, t r a i n i n g , e-mails, p e r f o r m a n c e appraisals, a d m i n f u n c t i o n s )
Attend Board/Committee Meetings P r o g r a m M a n a g e m e n t (Develop Inspection Forms, Self-Assessment F o r m , Regulations, M a i n t e n a n c e , etc.) Bi-Annual Staff M e e t i n g s / M a n a g e r M e e t i n g s
1,818 h o u r s
Total Time Positions N e e d e d
I n s p e c t o r s (2.0) W o r k l o a d FY 2017-18
1.0
# TIMES TASK
HOURSTO
TOTAL
PERFORMED
REFORM TASK
TIME/HOURS ANNUALLY*
Review Policies a n d P r o c e d u r e s / P r o d u c t Lists
58
8
464
Outsourcing Inspections*
58
40
2,320
Investigations
15
16
240
Report W r i t i n g
15
6
90
CGMP T r a i n i n g
2
80
160
Bi- A n n u a l Staff M e e t i n g s
4
24
96
9/28/16
Page 1 of 2
SB 1193 Outsourcing Facilities and Automated Drug Delivery Systems Workload Chart A d m i n Functions (travel claims, e - m a i l , etc. M o n t h l y C o n f e r e n c e calls
104
1
24
3
Total T i m e
104 72 3,546 (1,773 per Inspector)
Positions Needed
2.0
*The Inspectors will travel statewide and out of state to perform annual state mandated inspections of outsourcing facilities.
Inspections for licensure and renewal will ensure compliance with
requirements, pharmacy laws and regulations.
operational
The inspection process includes an inspection of the
outsourcing facility and review of policies and procedures, review of federal and state regulatory agency inspection reports, accreditation reports, certification reports of facilities or equipment premises conducted in prior 12 months, review of all sterile and nonsterile drug products compounded by the pharmacy as reported to the FDA in the prior 12 months and review of any disciplinary action taken by another state or the FDA. Inspectors will also review of the quantity and type of preparations compounded, collect evidence, write reports, interview staff, educate staff and issue orders of correction as appropriate. The inspectors investigate and/or mediate complaints alleging violations of the pharmacy practice act, specifically laws related to outsourcing facilities.
* * This includes inspections conducted alone by the Supervisor as well as semi-annual inspections with staff for training purposes, evaluating staff, etc.
9/28/16
Page 2 of 2
CURRENT FY 2016-17 Authorized positions: 100.8 BL 12-03 (999 Bianket): 3.7 Page 1
Executive Officer Virginia Herold
Department of C o n s u m e r Affairs
632-110-8916-001
Board of Pharmacy September 2016 Julia Ansel Chief of Enforcement C E A (Range A)
Anne Sodergren Assistant Executive Officer C E A (Range B ) 632-110-7500-001
Vacant
Vai'iiiit Chief of Enforcement C E A (Range A)
Limited TeriT!
632-110-7500-003
Fractional
632-110-7500-002
Blanket 907
Blanket
999
Christin e Acosta Super vising Insp ector
William Young Supervising Inspector
De'Bor a White Super vising Insp Ector
Anne Hunt Supervising Inspector
Joan Coyne Supervising Inspector
Janice Dang Supervising Inspector
Michael Ignacio Supervising Inspector
Antony Ngondara (LT) Supervising Inspector
632-110- 8874-011
632-110-8874-005
632-110- 8874-010
632-110-8874-008
632-110-8874-009
632-110-8874-003
632-110-8874-006
632-110-8874-600
Compounding
Compliance Investigation
Compliance Investigation
Compliance Investigation
Probation Monitoring/ Drug Diversion for Self-Use
Drug Diversion & Fraud
Drug Diversion & Fraud
Prescription Drug Abuse
Pharmacy Inspector (4)
Pharmacy Inspector (4)
Pharmacy Inspector (5)
Pharmacy Inspector (5)
Pharmacy Inspector (5)
Pharmacy Inspector (4)
Pharmacy Inspector (5)
.lulla Krunier (Tentative)
Valerie Sakamura
Diann Potter
Brandon Mutrux
Jennifer Hall
Steven Kyle
632-110-8876-004
632-110-8876-007
632-110-8876-005
632-110-8876-010
632-110-8876-600
Scott Huhii (Tentative)
Katherine Sill
Moneet Kaur
Patricia Peterson
Irina Top
632-110-8876-036
632-110-8876-006
632-110-8876-011
632-110-8876-601
Pharmacy Inspector (7)
Suzy Patell
Anna Yamada
632-110-8876-012
632-110-8876-003
Joshua Lee
Kavita Nankani (lentative)
632-110-8876-019
632-110-8876-016
632-110-8876-013
Michael Boluro-Ajayi
632-110-8876-031
632-110-8876-021
Margaret Panella-Spangler
Sejal Desai
632-110-8876-028
632-110-8876-025
Sara Mullen Phillip Wright
Ben Rustia
632-110-8876-606
632-110-8876-027
Vataiii (Ilixlnclt)
Joseph Wong
632-110-8876-607
Jeff Smith (RA)
Manisha Shafir
Connie Tang
632-110-8876-026
632-110-8876-602
Elhain Dclniic (i eiitativc)
632-110-8876-603
Simin Samari
Christopher Woo
632-110-8876-041
632-110-8876-014
Trang Song
Karla Retherford-Parreira
632-110-8876-043
632-110-8876-032
Craig Jeffers
Sarah Kim 632-110-8876-022
632-110-8876-035
632-110-8876-023
Anna Kalantar
Hilda Nip 632-110-8876-037
Lin Hokana 632-1 10-88"6-6llS
Noelle Randall
632-110-8876-034
632-110-8876-002
Michael Capili 632-110-8876-604
632-110-8876-033
632-110-8876-907
l.liula Paiiofslcy ( l entative) 632-110-8876-608
Denise Dukatz 632-110-8876-609
Executive Officer or Designee
Date
September 19, 2016 Classification & Pay Analyst
Date
Department of C o n s u m e r Affairs
Board of Pharmacy September 2016
Anne .Sodergren .As.slstaiil Executive Officer f E A (Range 1$) 632-110-7.300-001
Julia Ansel Cliicr of Eiiforcemciir f U A (Raiisc A) 632-110-7300-002
Clii istinc Aocsla Siipci \ising Inspector 10-8X74-01 I
t iiiiiptniiidiiiu
I'hiiiniacj Inspector (7)
Wiliiiini "t'oiiiig Siipcivlsiiig Inspector 632-110-8874-005
Dc'lJora White .Supervising In.spcetor 632-110-8874-010
Anne 1 lunl Supervising Inspector 632-110-8874-008
C'diiiplianee Investigation
Compliance Invcsliuaiion
Compliance Investigation
I'harniiicy Inspector
Pharniacy Inspector
j
(•»)
(•«)
j
Su/.y Palcll (A2-i iO-XX76-012
Anna Yamada i 632-110-8876-003 i
loshiia l.cc o.m-i iu-X87h-0l6
Kavita Natikaiii (1 ciitalivc) 632-110-8.876-013 •
Margaret I'aiieila-Spanglcr 63:-nO-,XX76-02X
Sejal Desui 63.2-110-8,876-025
Anna Kalaiilar 632-1 10-8876-606
lien RiLslia 632-110-8876-027 [
Craig Jcllcrs 632-1 iO-,S>S7(>-6()7
'
PROPOSED FY 2017-18 Authorized positions: 104.3 BL 12-03 (999 Bianket): 3.7 Page 1
Executive Officer Virginia 1 lerold 632-110-8916-001
Pharmacy Inspeclor (5)
.(ulia Kriiincr ( rcntallvc) 632-110-8876-019
I Valeric Sakamura ; 632-110-8876-004
Michael Holiiro-Ajayi 6.32-110-8876-021
i i
Phillip Wright 632-1 10-8876-023 Joseph Wong 632-110-8876-032 JclTSmUlKRA) 632-1 10-8876-907
Scott llitlin (Teiilalivc) 632-110-8876-031
1
Sara Mullen 632-1 10-8876-035 Vacant (lloditctt) ; 632-110-8876-043 Lin Hokana 632-110-8876-605
Proposed Supervising Inspector 632-110-8874-XXX
Oulsoiircing
I'liariiiacy Inspector (2) Proposed i>iC-l l ( ) - S S 7 ( . - . \ \
Vacant Vacant Chlefof Enforcement C E A (Range A) 632-110-7500-003
Joan Coyne Supervising liispcctor 632-110-8874-009 Probation Monitoring,' Drug Diversion lor Self-Use
Pharmacy Inspector
Blanket 9 0 7
Blanket
999
Fractional
Janice Dang Siipcrvlslng Inspector 632-110-8874-003
Michael Ignacio Supervising Inspector 632-110-8874-006
Antony Ngoiulaia (1.1) Supervising Inspector 632-i 10-8874-600
Drug Diversion & I raud
Drug Diversion & l-raiid
r'iv.scri|)t/on Drug Abuse
Pharinacy Inspector
I'liariitaey
Phaitiiiicy Inspector
litspcrtof (4)
(5) Diann Poller 632-110-8876-007
Brandon Mulrii.x 632-1 10-8876-005
.lennilcr Hall 632-110-8876-010
.Steven Kyle 632-110-8X76-600
Kalhcrinc Sill 632-1 10-8876-036
Moneet Kanr 632-110-8876-006
Patricia Pclersim 632-110-8876-011
Irina lop 632-110-8876-601
Hilda Nip 632-110-8876-037
Sarah Kim 632-110-8876-022
Manisha Slialh 632-110-8876-026
Connie J ang 632-110-8876-602
; |
Simin Samari 632-1 10-8876-041
Chi i.stopher Won 632-110-8876-014
Eiham Dciiiiie ( l eotalltc) 632-1 10-8876-034
Xocllc Randall 632-110-SS76-6O3
I
Ti ang Song 632-110-8876-002
Karla Rcthcrrord-Parrcira 632-110-8876-033
Michael Capili 632-110-8876-604
| |
Proposed ( ) t M IO-8.S7»-X.V\
Limited Term
!
Eliida I'anofskv (I ciitativc) 6.M-I !t)-,S876-60S Detiise Diikal/ |M2-i 1(1-8876-609 Executive Officer or D e s i g n e e
Date
S e p t e m b e r 19, 2 0 1 6 Classification & P a y Analyst
Date
0767 - State Board of Pharmacy Analysis of Fund Condition
01.03.17
(Dollars in Thousands)
2017-18 Governor's Budget
BEGINNING BALANCE
Prior Year Adjustment Adjusted Beginning Balance
ACTUAL 2015-16
Budget Act CY 2018-17
Governor's Budget BY 2017-18
BY+1 2018-19 $ $ $
10,093
1,666 4,819 18,726 205
25,416
$ $ $ $ $ $ $ $ $ $ $ $ $ $
$
25,416
$
25,416
$
33,141
$
35,509
26 1,165 20,655
$ $ $ $ $ $
21,193 481 27 1,347 23,048
$ $ $ $ $ $
7,725
$
10,093
$
$ $ $
7,725
1,666 4,819 18,726 205
17,862
$ $ $ $ $ $ $ $ $ $ $ $ $ $
$
17,862
30,603
$
28,380
$ $ $ $ $ $
20,050
20,085
$ $ $ $ $ $
$
10,518
$
$ $ $
11,742 26 11,768
$ $ $
10,518
$ $ $ $ $ $ $ $ $ $ $ $ $ $
2,288 3,529 12,748 193 4
1,841 3,547 12,283 191
1 13 10 18,835
$ $ $ $ $ $ $ $ $ $ $ $ $ $
$
18,835
$
10,518
7,725
10,093
R E V E N U E S AND T R A N S F E R S
Revenues: 125600 Other regulatory fees 125700 Other regulatory licenses and permits 125800 Renewal fees 125900 Delinquent fees 131700 Misc. revenue from local agencies 141200 Sales of documents 142500 Miscellaneous services to the public 150300 Income from surplus money investments 160100 Settlements and Judgements - AntI Trust Actions 150500 Interest Income From Interfund Loans 160400 Sale of fixed assets 161000 Escheat of unclaimed checks and warrants 161400 Miscellaneous revenues Totals, Revenues
49
-
-
-
25,416
Transfers to Other Funds: Totals, Revenues and Transfers Totals, Resources EXPENDITURES
Disbursements: 1110 Program Expenditures (State Operations) 1111 Program Expenditures (State Operations) Outsourcing Facility BCP (SB 1193) 8880 RISC (State Operations) 9900 Statewide Pro Rata Total Disbursements
35
-
19,464
-
21,658 449
1,347 23,454
FUND B A L A N C E
Reserve for economic uncertainties M o n t h s in R e s e r v e
6.1
4.0
5.2
12,055 6.1